Business
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLA
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"image","alt":"Amneal Pharmaceuticals LLC","displaySize":"","headline":null,"caption":"Amneal Pharmaceuticals LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/3fb94de605ddf51d0434711194cc8cc5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MVfw43aIERtNjvnCPqXoHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3fb94de605ddf51d0434711194cc8cc5","width":300,"height":133}},"lazy":false},{"type":"text","content":"Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025","length":84,"tagName":"p"},{"type":"text","content":"Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal","length":133,"tagName":"p"},{"type":"text","content":"BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compared to XOLAIR® in patients with Chronic Idiopathic Urticaria (CIU) or Chronic Spontaneous Urticaria (CSU) who remained symptomatic despite treatment with H1 antihistamines.","length":648,"tagName":"p"},{"type":"text","content":"Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of severe allergic asthma (>6 years old), chronic rhinosinusitis with nasal polyps (CRSwNP) (>18 years old), food allergies (>1 year old), and chronic spontaneous urticaria (>12 years old). It is typically administered in a hospital or clinic setting. The clinical study achieved its primary and secondary endpoints by establishing equivalence of therapeutic endpoints and comparable safety between ADL-018 and XOLAIR®. Participants received subcutaneous doses of either 150 mg or 300 mg every four weeks for a 24-week period. A total of 600 patients were enrolled, and efficacy and safety were evaluated in 400 patients who received the confirmatory dose of 300 mg. The primary effic...